Mobile Menu

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us
  • Menu
  • Skip to primary navigation
  • Skip to main content

https://eyecro.com

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us

Preclinical Ophthalmic Contract Research

Microemulsion Drug Ocular Penetration System MiDROPS™

While eyedrop formulations have been classically used to deliver soluble molecules to the anterior segment, there is a strong desire to develop formulations which can deliver lipophilic molecules into the eye by means of a stable and comfortable eyedrop formulation.  EyeCRO has developed MiDROPS™, a platform technology consisting of millions of formulations which can readily solubilize high concentrations of lipophilic agents and deliver them in abundant quantities to both the anterior segment and posterior segment. These single-phase microemulsions are self-assembling, and thus at a thermodynamic minimum which confers long term stability. Substantial proof of concept for delivery, efficacy, and safety has been demonstrated with multiple APIs in mice, rats, rabbits, and non-human primates. MiDROPS™ are patent protected in all major world jurisdictions.

CountryAward DatePatent Number
Australia 11/22/2018 2014244154
Canada 04/09/2019TBD
China P.R. 09/28/2018 ZL201480027477.7
European Union 05/23/2018 2968139
India 01/02/2019 305229
Japan 06/08/2018 6348567
United States 03/03/2015 8,968,775
United States 10/06/2015 9,149,453

MiDROPS™ are single-phase microemulsions


Contact us to learn how MiDROPS™ can help you deliver your drug with a comfortable and safe eyedrop

© 2023 · EyeCRO · All Rights Reserved.